Northwest Biotherapeutics patented a method to derive immature dendritic cells from monocytes using GM-CSF alone, without the need for additional cytokines. The cells can be matured for use in immunotherapy, including cancer treatment. GlobalData’s report on Northwest Biotherapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Northwest Biotherapeutics, Personalized cancer vaccines was a key innovation area identified from patents. Northwest Biotherapeutics's grant share as of January 2024 was 31%. Grant share is based on the ratio of number of grants to total number of patents.
Method for deriving immature dendritic cells from monocytic precursors
See Also:
A recently granted patent (Publication Number: US11827903B2) discloses a method for differentiating CD14+ CD1a- monocytic dendritic cell precursors into immature dendritic cells with specific surface markers. The method involves contacting the cell population with an isolation medium supplemented with a metal chelator to provide non-activated dendritic cell precursors. These precursors are then cultured in a low cellular avidity vessel with a dendritic cell culture media containing animal or human protein and granulocyte-macrophage colony stimulating factor, leading to the differentiation of immature dendritic cells with altered surface marker expression.
Furthermore, the patent claims include methods to prevent activation of the monocytic dendritic cell precursors by inhibiting adhesion to the culture vessel, the use of specific proteins like human serum albumin in the culture media, and the enrichment of dendritic cell precursors through tangential flow filtration. The method also involves subsequent steps such as contacting the immature dendritic cells with antigens of interest for antigen uptake and maturation agents like Bacillus Calmette-Guerin (BCG) or lipopolysaccharide (LPS). The disclosed method provides a detailed protocol for generating immature dendritic cells from specific cell populations, enhancing their potential applications in immunotherapy and antigen presentation studies.
To know more about GlobalData’s detailed insights on Northwest Biotherapeutics, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
